HCA Healthcare (HCA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $468.50, -0.41% vs the prior close of $470.44.
- Volume 1.12M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
HCA dips 0.4% to $468.50. Closed at $468.50, -0.41% vs the prior close of $470.44. Day range $467.28–$478.86, opened at $475.00.
HCA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — HCA dips 0.4% to $468.50
- Closed at $468.50, -0.41% vs the prior close of $470.44. Day range $467.28–$478.86, opened at $475.00.
- Volume was 1.12M shares, 0.9x its 50-day average of 1.29M.
- Price is +10.1% vs its 50-day average ($425.49) and +5.3% vs its 200-day average ($445.00).
- 52-week range $353.99–$556.52; today's close sits at 57% of that range, 15.8% below the 52-week high.
Oct 14, 2026 — HCA rises 2.1% to $470.44, a 3-month high, 6 up days in a row
- Closed at $470.44, +2.10% vs the prior close of $460.75. Day range $457.80–$472.39, opened at $463.09.
- Volume was 1.08M shares, 0.8x its 50-day average of 1.30M.
- Price is +10.9% vs its 50-day average ($424.31) and +5.7% vs its 200-day average ($445.02).
- 52-week range $353.99–$556.52; today's close sits at 57% of that range, 15.5% below the 52-week high.
- That makes 6 straight gains.
Oct 13, 2026 — HCA rises 0.5% to $460.75, a 3-month high, 5 up days in a row
- Closed at $460.75, +0.47% vs the prior close of $458.60. Day range $455.81–$462.44, opened at $459.54.
- Volume was 1.08M shares, 0.8x its 50-day average of 1.30M.
- Price is +8.9% vs its 50-day average ($422.92) and +3.5% vs its 200-day average ($445.06).
- 52-week range $353.99–$556.52; today's close sits at 53% of that range, 17.2% below the 52-week high.
- That makes 5 straight gains.
Oct 12, 2026 — HCA rises 1.7% to $458.60, a 3-month high, 4 up days in a row
- Closed at $458.60, +1.66% vs the prior close of $451.09. Day range $444.81–$460.28, opened at $450.58.
- Volume was 1.15M shares, 0.9x its 50-day average of 1.30M.
- Price is +8.7% vs its 50-day average ($421.83) and +3.0% vs its 200-day average ($445.12).
- 52-week range $353.99–$556.52; today's close sits at 52% of that range, 17.6% below the 52-week high.
- That makes 4 straight gains.
Oct 9, 2026 — HCA rises 1.4% to $451.09, a 3-month high, 3 up days in a row
- Closed at $451.09, +1.37% vs the prior close of $445.01. Day range $442.32–$452.39, opened at $444.58.
- Volume was 980.80K shares, 0.7x its 50-day average of 1.31M.
- Price is +7.2% vs its 50-day average ($420.71) and +1.3% vs its 200-day average ($445.20).
- 52-week range $353.99–$556.52; today's close sits at 48% of that range, 18.9% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — HCA rises 1.3% to $445.01, a 3-month high
- Closed at $445.01, +1.33% vs the prior close of $439.17. Day range $436.00–$446.48, opened at $436.95.
- Volume was 1.13M shares, 0.9x its 50-day average of 1.32M.
- Price is +6.1% vs its 50-day average ($419.61) and -0.1% vs its 200-day average ($445.31).
- 52-week range $353.99–$556.52; today's close sits at 45% of that range, 20.0% below the 52-week high.
Oct 7, 2026 — HCA rises 1.6% to $439.17, a 3-month high
- Closed at $439.17, +1.61% vs the prior close of $432.20. Day range $427.59–$442.59, opened at $431.76.
- Volume was 998.80K shares, 0.7x its 50-day average of 1.36M.
- Price is +4.8% vs its 50-day average ($418.87) and -1.4% vs its 200-day average ($445.45).
- 52-week range $353.99–$556.52; today's close sits at 42% of that range, 21.1% below the 52-week high.
Oct 6, 2026 — HCA dips 0.6% to $432.20
- Closed at $432.20, -0.63% vs the prior close of $434.92. Day range $429.49–$438.11, opened at $433.61.
- Volume was 999.20K shares, 0.7x its 50-day average of 1.38M.
- Price is +3.3% vs its 50-day average ($418.45) and -3.0% vs its 200-day average ($445.58).
- 52-week range $353.99–$556.52; today's close sits at 39% of that range, 22.3% below the 52-week high.
Oct 5, 2026 — HCA rises 1.9% to $434.92
- Closed at $434.92, +1.93% vs the prior close of $426.69. Day range $426.00–$437.27, opened at $426.70.
- Volume was 1.15M shares, 0.8x its 50-day average of 1.41M.
- Price is +4.1% vs its 50-day average ($417.60) and -2.4% vs its 200-day average ($445.78).
- 52-week range $353.99–$556.52; today's close sits at 40% of that range, 21.9% below the 52-week high.
Oct 2, 2026 — HCA rises 0.8% to $426.69
- Closed at $426.69, +0.78% vs the prior close of $423.39. Day range $424.23–$430.22, opened at $425.78.
- Volume was 929.80K shares, 0.7x its 50-day average of 1.42M.
- Price is +2.4% vs its 50-day average ($416.55) and -4.3% vs its 200-day average ($445.96).
- 52-week range $353.99–$556.52; today's close sits at 36% of that range, 23.3% below the 52-week high.
HCA latest news & SEC filings
Every SEC filing by or about HCA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 11, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 8.01 — Reported other events the company considers important.
Jul 28, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Key figures from this report aren't in the SEC's structured data yet (usually appears within a day or two).
Jul 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade HCA
- Last results release: Jul 24, 2026 (8-K Item 2.02). Previous ones: Jul 14, 2026, Apr 24, 2026, Jan 27, 2026. Based on that rhythm, the next report is likely around Oct 23, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.25% (largest 3.0%).
- Liquidity: about 1.34M shares (≈$625.49M) trade per day on average.
- 52-week position: $468.50 vs a range of $353.99–$556.52 (57% of the range).
- Dividends: last ex-dividend date Sep 16, 2026 ($0.78/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 13 sales; latest: Michael R Mcalevey sold 1,694 shares on Feb 18, 2026.
- Latest filings: 8-K Jul 29, 2026; 10-Q Jul 28, 2026; 8-K Jul 24, 2026.
- Share count: 221.84M shares outstanding (Apr 27, 2026), -7.8% vs a year earlier — the company has been reducing its share count.
- Listing: NYSE · industry: Services-General Medical & Surgical Hospitals, NEC.
HCA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 475.00 | 478.86 | 467.28 | 468.50 | 1.12M |
| Oct 14, 2026 | 463.09 | 472.39 | 457.80 | 470.44 | 1.08M |
| Oct 13, 2026 | 459.54 | 462.44 | 455.81 | 460.75 | 1.08M |
| Oct 12, 2026 | 450.58 | 460.28 | 444.81 | 458.60 | 1.15M |
| Oct 9, 2026 | 444.58 | 452.39 | 442.32 | 451.09 | 980.80K |
| Oct 8, 2026 | 436.95 | 446.48 | 436.00 | 445.01 | 1.13M |
| Oct 7, 2026 | 431.76 | 442.59 | 427.59 | 439.17 | 998.80K |
| Oct 6, 2026 | 433.61 | 438.11 | 429.49 | 432.20 | 999.20K |
| Oct 5, 2026 | 426.70 | 437.27 | 426.00 | 434.92 | 1.15M |
| Oct 2, 2026 | 425.78 | 430.22 | 424.23 | 426.69 | 929.80K |
| Oct 1, 2026 | 427.25 | 434.46 | 422.45 | 423.39 | 1.10M |
| Sep 30, 2026 | 430.25 | 434.07 | 425.96 | 426.74 | 1.24M |
| Sep 29, 2026 | 430.07 | 433.13 | 426.61 | 431.63 | 883.90K |
| Sep 28, 2026 | 431.16 | 443.15 | 431.16 | 432.60 | 1.11M |
| Sep 25, 2026 | 421.59 | 435.78 | 420.00 | 435.61 | 1.02M |
| Sep 24, 2026 | 437.36 | 442.21 | 423.39 | 423.48 | 1.05M |
| Sep 23, 2026 | 441.42 | 446.36 | 433.83 | 436.48 | 1.31M |
| Sep 22, 2026 | 426.37 | 442.52 | 426.37 | 438.12 | 1.50M |
| Sep 21, 2026 | 427.75 | 434.07 | 423.43 | 425.97 | 1.42M |
| Sep 18, 2026 | 429.17 | 436.14 | 425.37 | 427.71 | 5.44M |
About HCA Healthcare
HCA Healthcare (HCA) is listed on the NYSE and classified by the SEC under “Services-General Medical & Surgical Hospitals, NEC”. Its business address is in NASHVILLE, TN. Fiscal year ends December 31. SEC CIK 860730.
HCA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| John Chidsey | Director | Apr 30, 2026 |
| Nancy Ann Deparle | Director | Apr 30, 2026 |
| Thomas F Iii Frist | Director | Apr 30, 2026 |
| William R Frist | Director | Apr 30, 2026 |
| Samuel N Hazen | CEO | Feb 12, 2026 |
| Hugh F Johnston | Director | Apr 30, 2026 |
| Michael W Michelson | Director | Apr 30, 2026 |
| Wayne Joseph Riley | Director | Apr 30, 2026 |
| Andrea B Smith | Director | Apr 30, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jennifer Berres | SVP & Chief Human Res. Officer | Feb 12, 2026 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | Feb 12, 2026 |
| Jon M Foster | EVP and COO | Feb 12, 2026 |
| Samuel N Hazen | CEO | Feb 12, 2026 |
| Mike A Marks | EVP and CFO | May 11, 2026 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | Aug 28, 2026 |
| Erica Rossitto | SVP & Chief Nurse Executive | Feb 12, 2026 |
| Michael J Schlosser | EVP and Chief Clinical Officer | Sep 11, 2026 |
| Christopher F. Wyatt | SVP & Controller | Feb 12, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 18, 2026 | Michael R Mcalevey | Sale | 1,694 | $533.37 |
| Feb 11, 2026 | Christopher F. Wyatt | Sale | 4,000 | $505.00 |
| Feb 11, 2026 | Jennifer Berres | Sale | 4,010 | $526.16 |
| Feb 11, 2026 | Jennifer Berres | Sale | 4,010 | $503.00 |
| Feb 3, 2026 | Samuel N Hazen | Sale | 14,716 | $502.95 |
| Feb 3, 2026 | Samuel N Hazen | Sale | 5,002 | $502.15 |
| Feb 3, 2026 | Samuel N Hazen | Sale | 7,395 | $500.69 |
| Feb 3, 2026 | Samuel N Hazen | Sale | 6,189 | $500.02 |
| Feb 3, 2026 | Samuel N Hazen | Sale | 5,162 | $498.80 |
| Feb 3, 2026 | Samuel N Hazen | Sale | 4,293 | $498.12 |
| Feb 3, 2026 | Samuel N Hazen | Sale | 120 | $497.18 |
| Feb 3, 2026 | Michael S. Cuffe | Sale | 1,500 | $498.09 |
| Nov 5, 2025 | Michael R Mcalevey | Sale | 3,892 | $473.79 |
HCA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $75.60B | $6.78B | 28.33 | $12.64B |
| Dec 31, 2024 | $70.60B | $5.76B | 22.00 | $10.51B |
| Dec 31, 2023 | $64.97B | $5.24B | 18.97 | $9.43B |
| Dec 31, 2022 | $60.23B | $5.64B | 19.15 | $8.52B |
| Dec 31, 2021 | $58.75B | $6.96B | 21.16 | $8.96B |
Latest balance sheet: total assets $61.45B, total liabilities $45.62B, cash $940.00M (as of Mar 31, 2026).
HCA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 24, 2026 | 8-K Item 2.02 (results) | $382.19 |
| Jul 14, 2026 | 8-K Item 2.02 (results) | $363.60 |
| Apr 24, 2026 | 8-K Item 2.02 (results) | $432.46 |
| Jan 27, 2026 | 8-K Item 2.02 (results) | $505.84 |
| Oct 24, 2025 | 8-K Item 2.02 (results) | $447.04 |
| Jul 25, 2025 | 8-K Item 2.02 (results) | $334.32 |
| Apr 25, 2025 | 8-K Item 2.02 (results) | $327.92 |
| Jan 24, 2025 | 8-K Item 2.02 (results) | $313.07 |
| Oct 25, 2024 | 8-K Item 2.02 (results) | $363.55 |
| Jul 23, 2024 | 8-K Item 2.02 (results) | — |
| Apr 26, 2024 | 8-K Item 2.02 (results) | — |
| Jan 30, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Services-General Medical & Surgical Hospitals, NEC
Tenet Healthcare (THC)Universal Health Services (UHS)Surgery Partners (SGRY)Ardent Health (ARDT)Community Health Systems (CYH)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on HCA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.